<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345419</url>
  </required_header>
  <id_info>
    <org_study_id>COVID 19 treatment</org_study_id>
    <nct_id>NCT04345419</nct_id>
  </id_info>
  <brief_title>A Real-life Experience on Treatment of Patients With COVID 19</brief_title>
  <official_title>The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide,
      Ivermectin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide,
      Ivermectin on real life experience.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with decreased viral load</measure>
    <time_frame>6 months</time_frame>
    <description>the estimated number of patients with decreased viral load</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Faviprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Faviprevir as antiviral treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitazoxanide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Niclosamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Yomesan or niclosamide tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Other drugs as oseltamivir or combination of any of the above treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Chloroquine pills</description>
    <arm_group_label>Chloroquine</arm_group_label>
    <other_name>Alexoquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>Favipiravir as antiviral drug</description>
    <arm_group_label>Faviprevir</arm_group_label>
    <other_name>faviprevir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <other_name>alenia; nanazoxid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Ivermectin drug</description>
    <arm_group_label>Ivermectin</arm_group_label>
    <other_name>ivactin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide</intervention_name>
    <description>Yomesan or niclosamide tablets</description>
    <arm_group_label>Niclosamide</arm_group_label>
    <other_name>Yomean, Niclosamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other drugs</intervention_name>
    <description>other drugs as oseltamivir</description>
    <arm_group_label>Other drugs</arm_group_label>
    <other_name>Oseltamivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID 19 patients

        Exclusion Criteria:

          -  allergy or contraindication to the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, ass. prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University Faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eslam Saber, ass. lect</last_name>
    <role>Study Director</role>
    <affiliation>Tanta University Faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mai Khalaf, ass. lect.</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University Faculty of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam</last_name>
    <phone>+201147773440</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta university hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>assistant professor of tropical medicine and infectious diseases</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
    <mesh_term>Niclosamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

